Extended Antiphospholipid Antibodies Screening in Systemic Lupus Erythematosus Patients

1. PETRI M, ORBAI AM, ALARCÓN GS, GORDON C, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012; 64(8):2677-86.10.1002/art.34473Search in Google Scholar

2. MIYAKIS S, LOCKSHIN MD, ATSUMI T, BRANCH DW, BREY RL, CERVERA R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4(2):295-306.10.1111/j.1538-7836.2006.01753.xSearch in Google Scholar

3. PETRI M. Update on anti-phospholipid antibodies in SLE: the Hopkins’ Lupus Cohort. Lupus. 2010; 19(4):419-23.10.1177/0961203309360541Search in Google Scholar

4. WILLIS R, PIERANGELI SS. Pathophysiology of the antiphospholipid antibody syndrome. Auto Immun Highlights. 2011; 24; 2(2):35-5210.1007/s13317-011-0017-9Search in Google Scholar

5. MCCLAIN MT, ARBUCKLE MR, HEINLEN LD, DENNIS GJ, ROEBUCK J, RUBERTONE MV, et al. The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus. Arthritis Rheum. 2004; 50(4):1226-32.10.1002/art.20120Search in Google Scholar

6. GRIKA EP, ZIAKAS PD, ZINTZARAS E, MOUTSOPOULOS HM, VLACHOYIANNOPOULOS PG. Morbidity, mortality, and organ damage in patients with antiphospholipid syndrome. J Rheumatol. 2012; 39(3):516-23.10.3899/jrheum.110800Search in Google Scholar

7. CERVERA R, BUCCIARELLI S, PLASÍN MA, GÓMEZ-PUERTA JA, PLAZA J, PONS-ESTEL G, et al. Catastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group (European Forum on Antiphospholipid Antibodies). Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the “CAPS Registry”. J Autoimmun. 2009; 32(3-4):240-5.10.1016/j.jaut.2009.02.008Search in Google Scholar

8. SESTAK A, O’NEIL KM. Familial lupus and antiphospholipid syndrome. Lupus. 2007; 16(8):556-63.10.1177/0961203307078071Search in Google Scholar

9. RADWAY-BRIGHT EL, RAVIRAJAN CT, ISENBERG DA. The prevalence of antibodies to anionic phospholipids in patients with the primary antiphospholipid syndrome, systemic lupus erythematosus and their relatives and spouses. Rheumatology (Oxford). 2000; 39(4):427-31.10.1093/rheumatology/39.4.427Search in Google Scholar

10. RÚA-FIGUEROA I, LÓPEZ-LONGO FJ, CALVO-ALÉN J, GALINDO-IZQUIERDO M, LOZA E, GARCÍA DE YEBENES MJ, et al. Grupo de trabajo en Enfermedades Autoinmunes Sistémicas de la Sociedad Española de Reumatología (EAS-SER); Unidad de Investigación de la Sociedad Española de Reumatología (UI-SER). National registry of patients with systemic lupus erythematosus of the Spanish Society of Rheumatology: objectives and methodology. Reumatol Clin. 2014; 10(1):17-24.10.1016/j.reumae.2013.11.006Search in Google Scholar

11. UROWITZ MB, GLADMAN DD, IBAÑEZ D, FORTIN PR, BAE SC, GORDON C, et al. Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. Arthritis Care Res (Hoboken). 2012; 64(1):132-7.10.1002/acr.20648Search in Google Scholar

12. SZODORAY P, TARR T, TUMPEK J, KAPPELMAYER J, LAKOS G, POOR G, et al. Identification of rare anti-phospholipid/protein co-factor autoantibodies in patients with systemic lupus erythematosus. Autoimmunity. 2009; 42(6):497-506.10.1080/08916930902882731Search in Google Scholar

13. ABREU MM, DANOWSKI A, WAHL DG, AMIGO MC, TEKTONIDOU M, PACHECO MS, et al. The relevance of “non-criteria” clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. Autoimmun Rev. 2015; 14(5):401-14.10.1016/j.autrev.2015.01.002Search in Google Scholar

14. SAHIN M, DUZGUN N, TUNC SE, TUTKAK H. Clinical manifestations and antiphosphatidylserine antibodies in patients with systemic lupus erythematosus: is there an association? Clin Rheumatol. 2007; 26(2):154-60.10.1007/s10067-006-0249-7Search in Google Scholar

15. BUTKIEWICZ F, KASZUBA M, BRZEZIŃSKI M, IŻBICKI J, KUBIŚ M, LOPIŃSKI H, et al. Associations between the incidence of antiphosphatidylserine and antiphosphatidylethanolamine antibodies and clinical manifestations of systemic lupus erythematosus. Pol Arch Med Wewn. 2014; 124(11):573-8.10.20452/pamw.2489Search in Google Scholar

16. MATSUDA J, SAITOH N, GOTOH M, KAWASUGI K, GOHCHI K, TSUKAMOTO M. Phosphatidyl serine-dependent antiprothrombin antibody is exclusive to patients with lupus anticoagulant. Br J Rheumatol. 1996; 35(6):589-91.10.1093/rheumatology/35.6.589Search in Google Scholar

17. MATSUDA J, SANAKA T, NISHIZAWA A, GOTOH M, GOHCHI K. Two antiprothrombin antibodies against prothrombin and prothrombin-phosphatidyl serine show partial but not total identity. Blood Coagul Fibrinolysis. 2002; 13(8):697-702.10.1097/00001721-200212000-00005Search in Google Scholar

18. ZUILY S, DE LAAT B, MOHAMED S, KELCHTERMANS H, SHUMS Z, ALBESA R, NORMAN GL, et al. TAC(I)T investigators. Validity of the global anti-phospholipid syndrome score to predict thrombosis: a prospective multicentre cohort study. Rheumatology (Oxford). 2015 Jul 10.10.1093/rheumatology/kev238Search in Google Scholar

19. REYNAUD Q, LEGA JC, MISMETTI P, CHAPELLE C, WAHL D, CATHÉBRAS P, et al. Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev. 2014; 13(6):595-608.10.1016/j.autrev.2013.11.004Search in Google Scholar

20. BERTOLACCINI ML, MURRU V, SCIASCIA S, SANNA G, KHAMASHTA MA. The clinical value of testing for antibodies to phosphatidylethanolamine (aPE) in patients with systemic lupus erythematosus (SLE). Thromb Res 2012; 130(6):914-8.10.1016/j.thromres.2012.06.008Search in Google Scholar

21. SANMARCO M, BARDIN N. The contribution of antiphosphatidylethanolamine antibodies in the diagnosis of the antiphospholipid syndrome. Lupus 2012; 21(7):727-8.10.1177/0961203312437272Search in Google Scholar

22. WAHL DG, GUILLEMIN F, DE MAISTRE E, PERRET C, LECOMPTE T, THIBAUT G. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus – a meta-analysis. Lupus 1997; 6(5):467-73.10.1177/096120339700600510Search in Google Scholar

23. ROUBEY RA, PRATT CW, BUYON JP, WINFIELD JB. Lupus anticoagulant activity of autoimmune antiphospho-lipid antibodies is dependent upon beta 2-glycoprotein I. J Clin Invest. 1992; 90(3):1100-4.10.1172/JCI115926Search in Google Scholar

24. OOSTING JD, DERKSEN RH, ENTJES HT, BOUMA BN, DE GROOT PG. Lupus anticoagulant activity is frequently dependent on the presence of beta 2-glycoprotein I. Thromb Haemost 1992; 67(5):499-502.10.1055/s-0038-1648480Search in Google Scholar

25. DE GROOT PG, URBANUS RT, DERKSEN RH. Pathophysiology of thrombotic APS: where do we stand? Lupus. 2012; 21(7):704-7.10.1177/0961203312438631Search in Google Scholar

26. BERTOLACCINI ML, GOMEZ S, PAREJA JF, THEODORIDOU A, SANNA G, HUGHES GR, et al. Antiphospholipid antibody tests: spreading the net. Ann Rheum Dis 2005; 64(11):1639-43.10.1136/ard.2005.035824Search in Google Scholar

27. KEELING DM, WILSON AJ, MACKIE IJ, ISENBERG DA, MACHIN SJ. Lupus anticoagulant activity of some antiphospholipid antibodies against phospholipid bound beta 2 glycoprotein I. J Clin Pathol. 1993; 46(7):665-7.10.1136/jcp.46.7.665Search in Google Scholar

28. MCNEIL HP, SIMPSON RJ, CHESTERMAN CN, KRILIS SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA.1990; 87(11):4120-4.10.1073/pnas.87.11.4120Search in Google Scholar

29. HARPER BE, WILLS R, PIERANGELI SS. Pathophysiological mechanisms in antiphospholipid syndrome. Int J Clin Rheumtol. 2011; 6(2):157-171.10.2217/ijr.11.9Search in Google Scholar

30. DE LAAT B, DERKSEN RH, URBANUS RT, DE GROOT PG. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 2005; 105:1540-5.10.1182/blood-2004-09-3387Search in Google Scholar

31. RUFFATTI A, DEL ROSS T, CIPRIAN M, NUZZO M, RAMPUDDA M, BERTERO MT, et al. Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study. Ann Rheum Dis. 2009; 68(3):397-9.10.1136/ard.2008.096669Search in Google Scholar

32. DANOWSKI A, DE AZEVEDO MN, DE SOUZA PAPI JA, PETRI M. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. J Rheumatol. 2009; 36(6):1195-9.10.3899/jrheum.081194Search in Google Scholar

33. NEVILLE C, RAUCH J, KASSIS J, SOLYMOSS S, JOSEPH L, BELISLE P, et al. Antiphospholipid antibodies predict imminent vascular events independently from other risk factors in a prospective cohort. Thromb Haemost. 2009; 101(1):100-7.10.1160/TH08-06-0384Search in Google Scholar

34. BURGOS PI, MCGWIN G JR, REVEILLE JD, VILÁ LM, ALARCÓN GS. Factors predictive of thrombotic events in LUMINA, a multi-ethnic cohort of SLE patients (LXXII). Rheumatology (Oxford). 2010; 49(9):1720-5.10.1093/rheumatology/keq140Search in Google Scholar